Health care stocks were flat to higher premarket Tuesday with the Health Care Select Sector SPDR Fund (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) recently inactive.
Novo Nordisk's (NVO) weight-loss drug Wegovy is being offered in smaller doses of a compounded version by online weight-loss tool Noom, Reuters reported, citing senior company officials. Shares of Novo Nordisk were over 3% higher pre-bell.
NeurAxis (NRXS) shares surged past 160% after the company said the US Food and Drug Administration granted clearance to expand the use of its IB-Stim device for treating functional abdominal pain linked to functional dyspepsia and nausea in patients aged 8 to 21.
Zymeworks (ZYME) shares were up over 1% after the company said new preclinical data on its experimental respiratory inflammation drug ZW1528 has shown positive results.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。